Brentuximab Vedotin (BV) is an effective CD30-directed antibody-drug conjugate (ADC) for the treatment of patients with CD30+ lymphomas, which are refractory to standard therapy (22). This evidence concerns the gene TNFRSF8 and lymphoma.